Cell Line Collection: Doxycycline inducible SNCA
a-synuclein (SNCA) plays a pivotal role in the pathology of Parkinson’s disease.
To support research into this area, EBiSC provides a collection of lines engineered to enable flexible
and dose dependent induction of SNCA. The EBiSC lines BIONi010-C-24, BIONi010-C-43, BIONi010-C-44, BIONi010-C-49 and BIONi010-C-50
feature doxycycline-inducible SNCA expression inserted into the AAVS1 locus.
Ubiquitous Expression Models: BIONi010-C-24, BIONi010-C-43 and BIONi010-C-44
- SNCA expression is driven by the CAG promoter (broad expression across cell types).
- BIONi010-C-43 encodes wild-type SNCA.
- BIONi010-C-24 encodes the A53T pathogenic variant, with more information on its differentiation and use in assay development available here: https://pubmed.ncbi.nlm.nih.gov/34932569/
- BIONi010-C-44 encodes the A53T pathogenic variant.
- Both iPSC lines include HA-tagged constructs to distinguish exogenous from endogenous α-synuclein.
Neuron-Specific Expression Models: BIONi010-C-49 and BIONi010-C-50
- SNCA expression is controlled via the Synapsin-1 (hSyn) promoter.
- This restricts expression to neuronal cells.
- Both lines use neuron-specific M2rtTA for doxycycline inducibility.
- BIONi010-C-49 encodes wild-type SNCA.
- BIONi010-C-50 encodes the A53T pathogenic variant.
